- Home
- JRVR vs IKT Comparison
JRVR vs IKT Comparison
Compare JRVR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | IKT |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 240.1M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JRVR | IKT |
|---|---|---|
| Price | $3.92 | $1.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $7.33 | $5.00 |
| AVG Volume (30 Days) | 585.2K | ★ 683.9K |
| Earning Date | 05-04-2026 | 03-26-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.76 | $1.33 |
| 52 Week High | $7.20 | $2.26 |
Technical Indicators
Market Signals| Indicator | JRVR | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 47.13 |
| Support Level | $3.76 | $1.53 |
| Resistance Level | $4.42 | $1.90 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 20.45 | 36.67 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.